Medical device giant Stryker insists it is committed to a safe and healthy work environment after fire broke out at one of ...

This was the stock's second consecutive day of losses.

The medtech firm, which previously forecast a $200 million tariff impact for 2025, also raised its earnings outlook, citing ...

Stryker’s financials revealed total sales of $3.7bn in its medical surgery and neurotechnology business unit, up 17.3% on Q2 ...

Medical technology company Stryker (NYSE:SYK) reported Q2 CY2025 results , with sales up 11.1% year on year to $6.02 billion.

Stryker sells two product lines, OP-1 and Calstrux, for reconstructing bones damaged by surgery or injury. The products actively recruit new blood supply, promote bone growth, and fill voids in bones.

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Stryker, with a price target of $445.00. The company’s shares opened today at $372.32. Take advantage of ...

Revenue (GAAP) increased 11.1% to $6.0 billion, above analyst expectations. Adjusted earnings per share rose 11.4% to $3.13, exceeding consensus estimates. Full-year 2025 guidance was raised for both ...

As a result of its new model, Stryker IT truly operates on a global scale. It supports 38,000 tickets a month, averages an uptime of 99.6 percent, supports 240,000 digital meetings a week, and ...

This was the stock's fifth consecutive day of losses.